|
Gene: FAN1 |
Gene summary for FAN1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | FAN1 | Gene ID | 22909 |
Gene name | FANCD2 and FANCI associated nuclease 1 | |
Gene Alias | KIAA1018 | |
Cytomap | 15q13.3 | |
Gene Type | protein-coding | GO ID | GO:0000724 | UniProtAcc | Q9Y2M0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
22909 | FAN1 | HCC1_Meng | Human | Liver | HCC | 2.61e-21 | 4.08e-02 | 0.0246 |
22909 | FAN1 | HCC2_Meng | Human | Liver | HCC | 7.21e-08 | 5.80e-02 | 0.0107 |
22909 | FAN1 | HCC1 | Human | Liver | HCC | 1.37e-05 | 3.31e+00 | 0.5336 |
22909 | FAN1 | HCC2 | Human | Liver | HCC | 2.63e-09 | 2.97e+00 | 0.5341 |
22909 | FAN1 | S027 | Human | Liver | HCC | 4.52e-04 | 3.64e-01 | 0.2446 |
22909 | FAN1 | S029 | Human | Liver | HCC | 4.79e-02 | 2.67e-01 | 0.2581 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Thyroid | PTC | |
Thyroid | goiters | |
Thyroid | ATC |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0090305 | Liver | HCC | nucleic acid phosphodiester bond hydrolysis | 152/7958 | 261/18723 | 1.90e-07 | 3.46e-06 | 152 |
GO:00063021 | Liver | HCC | double-strand break repair | 131/7958 | 251/18723 | 1.17e-03 | 6.54e-03 | 131 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FAN1 | SNV | Missense_Mutation | c.1750N>A | p.Phe584Ile | p.F584I | Q9Y2M0 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-A2-A1G4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | SD | |
FAN1 | SNV | Missense_Mutation | novel | c.986N>T | p.Asp329Val | p.D329V | Q9Y2M0 | protein_coding | tolerated(0.08) | benign(0.289) | TCGA-AC-A3QP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
FAN1 | SNV | Missense_Mutation | novel | c.2034G>C | p.Gln678His | p.Q678H | Q9Y2M0 | protein_coding | deleterious(0) | possibly_damaging(0.907) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
FAN1 | SNV | Missense_Mutation | c.2977N>A | p.Glu993Lys | p.E993K | Q9Y2M0 | protein_coding | deleterious(0) | possibly_damaging(0.861) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
FAN1 | SNV | Missense_Mutation | novel | c.1758N>G | p.Ser586Arg | p.S586R | Q9Y2M0 | protein_coding | tolerated(0.46) | benign(0.003) | TCGA-E2-A570-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
FAN1 | deletion | Frame_Shift_Del | c.2996delC | p.Ala999ValfsTer3 | p.A999Vfs*3 | Q9Y2M0 | protein_coding | TCGA-A2-A04U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |||
FAN1 | deletion | Frame_Shift_Del | novel | c.1656_1674delTTCGTTGACCGACTCAATG | p.Phe552LeufsTer55 | p.F552Lfs*55 | Q9Y2M0 | protein_coding | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
FAN1 | insertion | Frame_Shift_Ins | novel | c.911_912insGATCATGTTATTCTCACCAGATTTC | p.Lys305IlefsTer17 | p.K305Ifs*17 | Q9Y2M0 | protein_coding | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
FAN1 | deletion | Frame_Shift_Del | novel | c.2744delN | p.Val917SerfsTer72 | p.V917Sfs*72 | Q9Y2M0 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
FAN1 | SNV | Missense_Mutation | novel | c.1211N>C | p.Val404Ala | p.V404A | Q9Y2M0 | protein_coding | deleterious(0) | benign(0.146) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |